KDC-MN-236 – Kodiac biolabs

Plain-language summaryIntrigue 69 / 100

Cariprazine (Vraylar) is a Hungarian-developed dopamine D2/D3 partial agonist from Gedeon Richter and AbbVie, approved by the FDA in 2015. It is structurally and mechanistically related to aripiprazole, but with a meaningful refinement: it preferentially binds the D3 receptor over D2 by roughly 6-fold. D3 receptors are concentrated in brain regions involved in motivation and cognition, which gives cariprazine a unique profile useful for the negative symptoms of schizophrenia (apathy, social withdrawal, cognitive blunting) where most antipsychotics fail. It is approved for schizophrenia, bipolar mania, bipolar depression, and as add-on for major depression. The very long half-lives of its active metabolites mean it takes weeks to reach steady state and weeks to wash out. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

62/100

A D3-dominant partial agonist with real clinical differentiation but a closing research novelty window

Cariprazine is one of those compounds where the mechanistic story is legitimately interesting but the research window has mostly closed. FDA-approved since 2015 across four indications, its clinical career is mature. The registration trials are done, the safety profile is established, and the field has moved from asking “does it work” to “how does it perform in practice against the other partial agonists.” That shift matters for how you score research relevance.

The D3 story is what keeps it on the radar. A Ki of roughly 0.085 nM at D3 is not a rounding error. That affinity actually exceeds endogenous dopamine’s own affinity for the same receptor, and no other marketed antipsychotic comes close to the D3 occupancy cariprazine produces at clinical doses. The biological rationale is solid: D3 receptors are enriched in mesolimbic and prefrontal circuits governing motivation, reward anticipation, and cognitive drive, which are exactly the domains where D2-heavy antipsychotics consistently fail. The 5-HT1A partial agonism (Ki ~2.6 nM) layers on top, adding complexity to any clean mechanistic interpretation but also contributing to its profile on anhedonia and depressive features.

The PRIDE trial is the clearest translational demonstration of that theory. Cariprazine versus risperidone in a predominantly negative-symptom schizophrenia population: statistically and clinically significant differences on the PANSS negative subscale and PSP. Risperidone is a competent D2 antagonist and cariprazine beat it on the domain D2 drugs have never served well. Thats real.

What we like: the D3 differentiation story holds up under scrutiny, the evidence base is among the strongest in the library (multiple phase 3 RCTs with hard primary endpoints), and the active metabolite pharmacology (DCAR and DDCAR together produce an effective half-life approaching one week) offers a pharmacokinetically unusual model that has its own research utility in steady-state receptor occupancy studies.

What we dont like: by 2026 this isnt a discovery compound. The primary clinical questions are answered. If you’re running a bench program, cariprazine is most likely to appear as a comparator or as a probe for D3 receptor contribution experiments, not as the main subject. The 5-HT1A activity complicates clean D3 interpretations, and investigators who need a tighter D3 probe may prefer less clinically cluttered ligands. The novelty clock started in 2002 and its audible.

Honest take: serious compound, legitimate clinical differentiation, fading research frontier. Investigators working on D3 circuitry, negative symptom pharmacology, or partial agonism dose-response modeling will find real utility here. For most other research programs, its a reference point rather than a primary target.

Novelty: 38
Mechanism promise: 65
In-category differentiation: 65
Evidence quality: 78
Translational signal: 72
Research bench value: 58

Rationale Cariprazine holds genuine mechanistic distinction within the dopamine partial agonist class via subnanomolar D3 affinity exceeding endogenous dopamine, with strong multi-trial clinical evidence across four approved indications; novelty is suppressed because the compound is a 2015-approved drug whose primary clinical questions are settled, and bench utility is real but narrowly concentrated in D3 receptor biology and negative-symptom circuitry research.

Dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist atypical antipsychotic

A D3-preferring dopamine receptor partial agonist developed by Gedeon Richter as an atypical antipsychotic, distinguished from aripiprazole and brexpiprazole by subnanomolar D3 affinity exceeding that of endogenous dopamine and by the generation of two pharmacologically active long-lived metabolites that collectively produce an effective half-life of approximately one week.

Abstract

Cariprazine (RGH-188; marketed as Vraylar) is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist approved by the United States Food and Drug Administration for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder (bipolar depression), and adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant therapy. The compound was discovered by Gedeon Richter Plc. in Budapest, Hungary, first synthesized in 2002, and advanced through clinical development in partnership with Forest Laboratories (subsequently Actavis, Allergan, and AbbVie), receiving initial FDA approval in September 2015 and European Medicines Agency approval in 2017 under the trade name Reagila. Cariprazine is pharmacologically distinguished from the other clinically marketed dopamine partial agonist antipsychotics (aripiprazole, brexpiprazole) by its exceptionally high affinity for the dopamine D3 receptor (Ki approximately 0.085 nM), which exceeds the affinity of endogenous dopamine for the same receptor and produces a degree of D3 occupancy at clinical doses that is not achievable by any other marketed antipsychotic. The D3-preferring profile, with approximately 6- to 8-fold selectivity over D2, is hypothesized to underwrite the compound’s differentiated efficacy on negative symptoms of schizophrenia, cognitive impairment, anhedonia, and motivational deficits, domains that are poorly served by D2-predominant antipsychotic pharmacology. Cariprazine additionally binds the serotonin 5-HT1A receptor as a partial agonist (Ki approximately 2.6 nM) and the serotonin 5-HT2B receptor with high affinity (Ki approximately 0.6 nM), while showing low affinity for histamine H1, muscarinic, and alpha-1 adrenergic receptors, a selectivity profile that predicts low sedation, low anticholinergic burden, and low orthostatic hypotension relative to the broader atypical antipsychotic class.

The pharmacokinetic profile of cariprazine is dominated by its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both of which possess pharmacological activity comparable to the parent compound at D3, D2, and 5-HT1A receptors. The parent compound has a half-life of 2 to 4 days; DCAR has a half-life of 1 to 2 days; and DDCAR, the predominant circulating active species at steady state, has a half-life of 1 to 3 weeks. The effective half-life of total active moieties is approximately 1 week, with steady-state equilibrium achieved at approximately 3 weeks of daily dosing. This pharmacokinetic profile has important implications for dose titration (clinical effects may lag dose changes by days to weeks), for drug-drug interactions (strong CYP3A4 inhibitors require dose reduction; strong CYP3A4 inducers are contraindicated), and for washout after discontinuation (pharmacological activity persists for several weeks).

The clinical evidence base comprises multiple Phase 2 and Phase 3 randomized controlled trials across four approved indications, a head-to-head Phase 3b trial against risperidone for predominant negative symptoms of schizophrenia (demonstrating statistically significant superiority on the PANSS factor score for negative symptoms), and relapse prevention data in schizophrenia. The adverse-event profile is characterized by akathisia and extrapyramidal symptoms as the most common treatment-emergent adverse events (dose-dependent, typically mild to moderate), with a comparatively favorable metabolic profile (minimal weight gain, negligible effects on glucose and lipid parameters) and low prolactin elevation relative to other atypical antipsychotics. This monograph reviews the chemistry, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence across all approved and investigational indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative atypical antipsychotic agents against cariprazine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1503Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-236

Cariprazine

Abstract

Read the full monograph